Biobetters Vs Biosimilars

Biosimilars differ from generic drugs by their characteristics, their raw materials and manufacturing processes. Differences between generics and biosimilars focus on product development, marketing authorization, and post-registration monitoring. There are essential differences between the two regulatory pathways relating to biosimilars. Unlike generic medicines, where the active ingredients are identical, biosimilars, by definition, are not likely to be identical to the originator biologic. They are similar, but not the same

The case of “biobetters” illustrates a product differentiation strategy comparable to what we see with supergenerics and hybrid products, and is likely to bring a new dynamic of competition to the market.  These products can also improve patient access to more affordable innovative products. In turn, the whole concept of a new pharmaceutical product is evolving.

  • The future of biosimilars in specific emerging markets
  • Safety in biosimilar development
  • Methods for biobetter development
  • Marketing Biosimilars in the EU
  • What impact does a modified immunological profile have on the clinical outcome?
  • Importance of Phase III immunological trials, analytical expertise
  • Ultra potent antibodies and ligand traps
  • Glycoengineering to increase potency
  • Clinical approach and safety in biosimilar development
  • Pharmacokinetic studies of approved biosimilars

Related Conference of Biobetters Vs Biosimilars

December 02, 03, 2019

15th Annual Congress on Pharmacology and Toxicology

Paris, France
February 12-13, 2020

14th Global Pharmacovigilance and Clinical Trials Summit

Sydney, Australia
February 12-13, 2020

2nd International Conference on Biosimilars & Pharmaceuticals

Auckland, New Zealand
March 25-26, 2020

23rd Asia Pacific Pharma Congress

| Singapore
April 01-02, 2020

13th European Biosimilars Congress 2020

London, UK
April 09-10, 2020

World Pharma Expo

Bangkok, Thailand
April 27-28, 2020

5th Pharmaceutical Chemistry Conference

Prague, Czech Republic
April 27-28, 2020

7th European Biopharma Congress

Prague, Czech Republic
May 06-07, 2020

15th Annual Meet on Euro Ethnopharmacology

Prague | Czech Republic
May 18-19, 2020

30th Annual European Pharma Congress

Berlin, Germany
May 27- 28, 2020

14 th World Drug Delivery Summit

| London, UK
June 15-16, 2020

cancer-research-2020

Barcelona, Spain
June 18-19 | 2020

6th World Congress on Medicinal Plants and Marine Drugs

Amsterdam, Netherlands
June 24-25, 2020

25th International Congress on Pharmaceutical Biotechnology

Amsterdam | Netherlands
June 29-30, 2020

12th World Congress on Neuropharmacology

Athens, Greece
August 17-18, 2020

Innovation in Drug Design Techniques and Pharmacology

| Paris, France
August 26-27, 2020

33rdWorld Congress on Pharmacology

Barcelona, Spain
September 07-08, 2020

Global Summit on Generic Drugs and Quality Control

| Prague, Czech Republic
September 10-11, 2020

World Congress on Rare Diseases & Orphan Drugs

| Prague, Czech Republic
September 21-22, 2020

35th World Pharmacology and Toxicology Forum

Tokyo, Japan
November 09-10, 2020

2nd World Congress on Drug Discovery and Drug Design

| Tokyo, Japan
November 09-10, 2020

Annual Meet on Pharmacovigilance & Drug Safety

Tokyo, Japan
November 09-10 , 2020

Asia Pacific Pharmaceutics & Drug Delivery Congress

| Tokyo , Japan
December 02-03, 2020

International Conference onBiotechnology and Healthcare

Auckland, Newzealand
December 06-07, 2021

22nd Pharma Middle East Congress

Dubai, UAE

Biobetters Vs Biosimilars Conference Speakers

Recommended Sessions

Related Journals

Are you interested in